Asymptornatic incidence and duration of prostate cancer

American Journal of Epidemiology

Volumn 148, Issue 8, 1998, Pages 775-785

  Etzioni, Ruth ^a   Cha, Raymond ^a   Feuer, Eric J ^b   Davidov, Ori ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Disease progression; Natural history; Prevalence; Prostatic neoplasms; SEER program

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER INCIDENCE; CANCER SCREENING; CAUCASIAN; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; PREVALENCE; PROSTATE CANCER; SYMPTOMATOLOGY; AFRICAN AMERICAN; AGE DISTRIBUTION; CANCER REGISTRY; DISEASE COURSE; INCIDENCE; MASS SCREENING; MIDDLE AGED; PROSTATE TUMOR; STATISTICS; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; PREVALENCE; PROSTATIC NEOPLASMS; SEER PROGRAM; UNITED STATES;

EID: 0032531427     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a009698     Document Type: Article

References (19)

1. Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990;143:742-6.
2. Guileyardo JM, Johnson WD, Welsh RA, et al. Prevalence of latent prostatic carcinoma in two US populations. J Natl Cancer Inst 1980;65:311-16.
3. SEER cancer statistics review: 1973-1990. Bethesda, MD: US Department of Health and Human Services, Public Health Service National Institutes of Health, National Cancer Institute 1993. (DHHS publication no. (NIH)93-2789).
4. Whittemore AS, Lele C, Friedman GD, et al. Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst 1995;87:354-60.
5. Morrell CH, Pearson JD, Carter HB, et al. Estimating unknown transition times using a piecewise nonlinear mixed-effects model in men with prostate cancer. J Am Stat Assoc 1995;90:45-53.
6. Whittemore AS, Keller JB, Betensky R. Low-grade, latent prostate cancer volume: predictor of clinical cancer incidence? J Natl Cancer Inst 1991;83:1231-5.
7. Leske MC, Ederer F, Podgor M. Estimating incidence from age-specific prevalence in glaucoma. Am J Epidemiol 1981; 113:606-13.
8. Wun LM, Merrill RM, Feuer EJ. Estimating lifetime and age-conditional risks of developing cancer. Lifetime Data Anal 1998;4:169-86.
9. Freeman J, Hutchison GB. Prevalence, incidence and duration. Am J Epidemiol 1980;112:707-23.
10. Cowen ME, Chartrand M, Weitzel WF. A Markov model of the natural history of prostate cancer. J Clin Epidemiol 1994;47:3-21.
11. Gail M. A review and critique of some models used in competing risk analysis. Biometrics 1975;31:209-22.
12. Forty-five years of cancer incidence in Connecticut: 1935-79. Natl Cancer Inst Monogr 1986;70:1-706.
13. National Center for Health Statistics: vital statistics of the United States, 1986. Vol II: Mortality, Part A. Washington, DC: US GPO, 1988. (DHHS publication no. (PHS)88-1122).
14. Yax LK. US Census Bureau, national population estimates (online), 1998. Available from Homepage of US Census Bureau: http://www.census.gov. Accessed 1998, April 21.
15. Potosky AL, Kessler L, Gridley G, et al. Rise in prostatic cancer incidence associated with increased use of transurethral resection. J Natl Cancer Inst 1990;82:1624-8.
16. Podgor MJ, Leske MC. Estimating incidence from age-specific prevalence for irreversible diseases with differential mortality. Stat Med 1986;5:573-8.
17. Albert A, Gertman PM, Louis TA. Screening for the early detection of cancer. 1. The temporal natural history of a progressive disease state. Math Biosci 1978;40:1-59.
18. Sakr WA, Haas GP, Cassin BF, et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150:379-85.
19. Feuer EJ, Wun LM. DEVCAN: Probability of DEVeloping CANcer software, version 3.11. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, 1994.